ID   PMVK_HUMAN              Reviewed;         192 AA.
AC   Q15126; Q5TZW9;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   12-APR-2017, entry version 152.
DE   RecName: Full=Phosphomevalonate kinase;
DE            Short=PMKase;
DE            Short=hPMK;
DE            EC=2.7.4.2;
GN   Name=PMVK; Synonyms=PMKI;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=8663599; DOI=10.1074/jbc.271.29.17330;
RA   Chambliss K.L., Slaughter C.A., Schreiner R., Hoffmann G.F.,
RA   Gibson K.M.;
RT   "Molecular cloning of human phosphomevalonate kinase and
RT   identification of a consensus peroxisomal targeting sequence.";
RL   J. Biol. Chem. 271:17330-17334(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-125.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 33-192, INDUCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=10191291;
RA   Olivier L.M., Chambliss K.L., Gibson K.M., Krisans S.K.;
RT   "Characterization of phosphomevalonate kinase: chromosomal
RT   localization, regulation, and subcellular targeting.";
RL   J. Lipid Res. 40:672-679(1999).
RN   [5]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=9392419;
RA   Hinson D.D., Chambliss K.L., Toth M.J., Tanaka R.D., Gibson K.M.;
RT   "Post-translational regulation of mevalonate kinase by intermediates
RT   of the cholesterol and nonsterol isoprene biosynthetic pathways.";
RL   J. Lipid Res. 38:2216-2223(1997).
RN   [6]
RP   FUNCTION, MUTAGENESIS OF LYS-17; ARG-18; LYS-19; LYS-22 AND ASP-23,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND ATP-BINDING.
RX   PubMed=16519518; DOI=10.1021/bi052231u;
RA   Herdendorf T.J., Miziorko H.M.;
RT   "Phosphomevalonate kinase: functional investigation of the recombinant
RT   human enzyme.";
RL   Biochemistry 45:3235-3242(2006).
RN   [7]
RP   FUNCTION, MUTAGENESIS OF LYS-48; LYS-69; ARG-73; ARG-84; ARG-110;
RP   ARG-111 AND ARG-141, AND ATP-BINDING.
RX   PubMed=17902708; DOI=10.1021/bi701408t;
RA   Herdendorf T.J., Miziorko H.M.;
RT   "Functional evaluation of conserved basic residues in human
RT   phosphomevalonate kinase.";
RL   Biochemistry 46:11780-11788(2007).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   INVOLVEMENT IN POROK1, AND VARIANT POROK1 GLU-69.
RX   PubMed=26202976; DOI=10.7554/eLife.06322;
RA   Zhang Z., Li C., Wu F., Ma R., Luan J., Yang F., Liu W., Wang L.,
RA   Zhang S., Liu Y., Gu J., Hua W., Fan M., Peng H., Meng X., Song N.,
RA   Bi X., Gu C., Zhang Z., Huang Q., Chen L., Xiang L., Xu J., Zheng Z.,
RA   Jiang Z.;
RT   "Genomic variations of the mevalonate pathway in porokeratosis.";
RL   Elife 4:E06322-E06322(2015).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.76 ANGSTROMS), ATP-BINDING, AND SUBSTRATE
RP   BINDING.
RX   PubMed=18618710; DOI=10.1002/prot.22151;
RA   Chang Q., Yan X.-X., Gu S.-Y., Liu J.-F., Liang D.-C.;
RT   "Crystal structure of human phosphomevalonate kinase at 1.8 A
RT   resolution.";
RL   Proteins 73:254-258(2008).
CC   -!- CATALYTIC ACTIVITY: ATP + (R)-5-phosphomevalonate = ADP + (R)-5-
CC       diphosphomevalonate. {ECO:0000269|PubMed:8663599}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=25 uM for (R)-5-phosphomevalonate
CC         {ECO:0000269|PubMed:16519518, ECO:0000269|PubMed:9392419};
CC         KM=0.26 mM for ATP {ECO:0000269|PubMed:16519518,
CC         ECO:0000269|PubMed:9392419};
CC         Vmax=46.4 umol/min/mg enzyme with (R)-5-phosphomevalonate as
CC         substrate {ECO:0000269|PubMed:16519518,
CC         ECO:0000269|PubMed:9392419};
CC         Vmax=52 umol/min/mg enzyme with ATP as substrate
CC         {ECO:0000269|PubMed:16519518, ECO:0000269|PubMed:9392419};
CC   -!- PATHWAY: Isoprenoid biosynthesis; isopentenyl diphosphate
CC       biosynthesis via mevalonate pathway; isopentenyl diphosphate from
CC       (R)-mevalonate: step 2/3.
CC   -!- SUBUNIT: Monomer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Peroxisome {ECO:0000269|PubMed:10191291}.
CC   -!- TISSUE SPECIFICITY: Heart, liver, skeletal muscle, kidney, and
CC       pancreas. Lower level in brain, placenta and lung.
CC       {ECO:0000269|PubMed:8663599}.
CC   -!- INDUCTION: By sterol. {ECO:0000269|PubMed:10191291}.
CC   -!- DISEASE: Porokeratosis 1, multiple types (POROK1) [MIM:175800]: A
CC       form of porokeratosis, a disorder of faulty keratinization
CC       characterized by one or more atrophic patches surrounded by a
CC       distinctive hyperkeratotic ridgelike border called the cornoid
CC       lamella. The keratotic lesions can progress to overt cutaneous
CC       neoplasms, typically squamous cell carcinomas. Multiple clinical
CC       variants of porokeratosis are recognized, including porokeratosis
CC       of Mibelli, linear porokeratosis, disseminated superficial actinic
CC       porokeratosis, palmoplantar porokeratosis, and punctate
CC       porokeratosis. Different clinical presentations can be observed
CC       among members of the same family. Individuals expressing more than
CC       one variant have also been reported.
CC       {ECO:0000269|PubMed:26202976}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L77213; AAC37593.1; -; mRNA.
DR   EMBL; BT019976; AAV38779.1; -; mRNA.
DR   EMBL; BC006089; AAH06089.1; -; mRNA.
DR   EMBL; BC007694; AAH07694.1; -; mRNA.
DR   EMBL; AF026069; AAC60791.1; -; Genomic_DNA.
DR   CCDS; CCDS1073.1; -.
DR   RefSeq; NP_006547.1; NM_006556.3.
DR   UniGene; Hs.30954; -.
DR   PDB; 3CH4; X-ray; 1.76 A; B=1-192.
DR   PDBsum; 3CH4; -.
DR   ProteinModelPortal; Q15126; -.
DR   SMR; Q15126; -.
DR   BioGrid; 115897; 24.
DR   IntAct; Q15126; 3.
DR   MINT; MINT-7034566; -.
DR   STRING; 9606.ENSP00000357452; -.
DR   GuidetoPHARMACOLOGY; 641; -.
DR   SwissLipids; SLP:000001241; -.
DR   iPTMnet; Q15126; -.
DR   PhosphoSitePlus; Q15126; -.
DR   BioMuta; PMVK; -.
DR   DMDM; 3024422; -.
DR   REPRODUCTION-2DPAGE; IPI00220648; -.
DR   EPD; Q15126; -.
DR   PaxDb; Q15126; -.
DR   PeptideAtlas; Q15126; -.
DR   PRIDE; Q15126; -.
DR   DNASU; 10654; -.
DR   Ensembl; ENST00000368467; ENSP00000357452; ENSG00000163344.
DR   GeneID; 10654; -.
DR   KEGG; hsa:10654; -.
DR   CTD; 10654; -.
DR   DisGeNET; 10654; -.
DR   GeneCards; PMVK; -.
DR   HGNC; HGNC:9141; PMVK.
DR   HPA; HPA029900; -.
DR   MalaCards; PMVK; -.
DR   MIM; 175800; phenotype.
DR   MIM; 607622; gene.
DR   neXtProt; NX_Q15126; -.
DR   OpenTargets; ENSG00000163344; -.
DR   PharmGKB; PA33465; -.
DR   eggNOG; ENOG410IZWN; Eukaryota.
DR   eggNOG; ENOG4111IXB; LUCA.
DR   GeneTree; ENSGT00390000014801; -.
DR   HOGENOM; HOG000261666; -.
DR   HOVERGEN; HBG003277; -.
DR   InParanoid; Q15126; -.
DR   KO; K13273; -.
DR   OMA; KNDIKWF; -.
DR   OrthoDB; EOG091G0PNO; -.
DR   PhylomeDB; Q15126; -.
DR   TreeFam; TF312935; -.
DR   BioCyc; MetaCyc:HS08830-MONOMER; -.
DR   BRENDA; 2.7.4.2; 2681.
DR   Reactome; R-HSA-191273; Cholesterol biosynthesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   SABIO-RK; Q15126; -.
DR   UniPathway; UPA00057; UER00099.
DR   ChiTaRS; PMVK; human.
DR   EvolutionaryTrace; Q15126; -.
DR   GenomeRNAi; 10654; -.
DR   PRO; PR:Q15126; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000163344; -.
DR   CleanEx; HS_PMVK; -.
DR   ExpressionAtlas; Q15126; baseline and differential.
DR   Genevisible; Q15126; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0004631; F:phosphomevalonate kinase activity; IDA:UniProtKB.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0019287; P:isopentenyl diphosphate biosynthetic process, mevalonate pathway; IBA:GO_Central.
DR   GO; GO:0070723; P:response to cholesterol; IEP:UniProtKB.
DR   GO; GO:0016126; P:sterol biosynthetic process; IDA:UniProtKB.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005919; Pmev_kin_anim.
DR   PANTHER; PTHR13101; PTHR13101; 1.
DR   Pfam; PF04275; P-mevalo_kinase; 1.
DR   PIRSF; PIRSF036639; PMK_anim; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR01223; Pmev_kin_anim; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cholesterol biosynthesis;
KW   Cholesterol metabolism; Complete proteome; Disease mutation; Kinase;
KW   Lipid biosynthesis; Lipid metabolism; Nucleotide-binding; Peroxisome;
KW   Polymorphism; Reference proteome; Steroid biosynthesis;
KW   Steroid metabolism; Sterol biosynthesis; Sterol metabolism;
KW   Transferase.
FT   CHAIN         1    192       Phosphomevalonate kinase.
FT                                /FTId=PRO_0000058472.
FT   NP_BIND      17     23       ATP. {ECO:0000305|PubMed:16519518,
FT                                ECO:0000305|PubMed:18618710}.
FT   MOTIF       190    192       Microbody targeting signal.
FT                                {ECO:0000255}.
FT   BINDING     141    141       ATP. {ECO:0000305|PubMed:17902708,
FT                                ECO:0000305|PubMed:18618710}.
FT   BINDING     170    170       Substrate. {ECO:0000269|PubMed:18618710}.
FT   BINDING     171    171       ATP. {ECO:0000305|PubMed:18618710}.
FT   BINDING     176    176       ATP. {ECO:0000305|PubMed:18618710}.
FT   BINDING     180    180       ATP. {ECO:0000305|PubMed:18618710}.
FT   VARIANT      69     69       K -> E (in POROK1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26202976}.
FT                                /FTId=VAR_075051.
FT   VARIANT     125    125       V -> M (in dbSNP:rs16836525).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_051283.
FT   MUTAGEN      17     17       K->M: Approximately 8-fold decrease in
FT                                Vmax for MgATP and R-MVP. Approximately
FT                                5-fold increase in Km for MgATP and R-
FT                                MVP. {ECO:0000269|PubMed:16519518}.
FT   MUTAGEN      18     18       R->Q: Approximately 85-fold decrease in
FT                                Vmax for MgATP and R-MVP. Approximately
FT                                5-fold increase in Km for MgATP and R-
FT                                MVP. {ECO:0000269|PubMed:16519518}.
FT   MUTAGEN      19     19       K->M: Approximately 9-fold decrease in
FT                                Vmax for MgATP and R-MVP. Approximately
FT                                10-fold increase in Km for MgATP and R-
FT                                MVP. {ECO:0000269|PubMed:16519518}.
FT   MUTAGEN      22     22       K->M: Approximately 100000-fold decrease
FT                                in Vmax for MgATP.
FT                                {ECO:0000269|PubMed:16519518}.
FT   MUTAGEN      23     23       D->N: Approximately 7-fold decrease in
FT                                Vmax for MgATP and R-MVP. Approximately
FT                                10-fold increase in Km for MgATP and 5-
FT                                fold increase in Km for R-MVP.
FT                                {ECO:0000269|PubMed:16519518}.
FT   MUTAGEN      48     48       K->M: Approximately 1400-fold decrease in
FT                                Vmax for MgATP and R-MVP. Approximately
FT                                3-fold increase in Km for MgATP and R-
FT                                MVP. {ECO:0000269|PubMed:17902708}.
FT   MUTAGEN      69     69       K->M: Approximately 500-fold decrease in
FT                                Vmax for MgATP and R-MVP. Approximately
FT                                3-fold increase in Km for MgATP and R-
FT                                MVP. {ECO:0000269|PubMed:17902708}.
FT   MUTAGEN      73     73       R->M: Approximately 3000-fold decrease in
FT                                Vmax for MgATP and R-MVP. No change in Km
FT                                for MgATP and approximately 3-fold
FT                                increase in Km for R-MVP.
FT                                {ECO:0000269|PubMed:17902708}.
FT   MUTAGEN      84     84       R->M: Approximately 10-fold decrease in
FT                                Vmax for MgATP and R-MVP. Approximately
FT                                3-fold increase in Km for MgATP and 50-
FT                                fold increase in Km for R-MVP.
FT                                {ECO:0000269|PubMed:17902708}.
FT   MUTAGEN      93     93       R->M: Almost no change in Km and Vmax for
FT                                MgATP and R-MVP.
FT   MUTAGEN     110    110       R->M: Approximately 20000-fold decrease
FT                                in Vmax for MgATP.
FT                                {ECO:0000269|PubMed:17902708}.
FT   MUTAGEN     111    111       R->M: Approximately 65-fold decrease in
FT                                Vmax for MgATP and R-MVP. Approximately
FT                                8-fold increase in Km for MgATP and 60-
FT                                fold increase in Km for R-MVP.
FT                                {ECO:0000269|PubMed:17902708}.
FT   MUTAGEN     130    130       R->M: Approximately 4-fold decrease in
FT                                Vmax for MgATP and R-MVP. Approximately
FT                                3-fold increase in Km for MgATP and R-
FT                                MVP.
FT   MUTAGEN     138    138       R->M: Approximately 3-fold decrease in
FT                                Vmax for MgATP and R-MVP. Approximately
FT                                5-fold increase in Km for MgATP and no
FT                                change in Km for R-MVP.
FT   MUTAGEN     141    141       R->M: Approximately 15-fold decrease in
FT                                Vmax for MgATP and R-MVP. Approximately
FT                                50-fold increase in Km for MgATP and
FT                                approximately 7-fold in Km for R-MVP.
FT                                {ECO:0000269|PubMed:17902708}.
FT   STRAND        9     16       {ECO:0000244|PDB:3CH4}.
FT   HELIX        22     33       {ECO:0000244|PDB:3CH4}.
FT   TURN         35     37       {ECO:0000244|PDB:3CH4}.
FT   STRAND       38     41       {ECO:0000244|PDB:3CH4}.
FT   HELIX        44     53       {ECO:0000244|PDB:3CH4}.
FT   TURN         54     56       {ECO:0000244|PDB:3CH4}.
FT   HELIX        72     86       {ECO:0000244|PDB:3CH4}.
FT   TURN         88     91       {ECO:0000244|PDB:3CH4}.
FT   HELIX        92     95       {ECO:0000244|PDB:3CH4}.
FT   STRAND      102    106       {ECO:0000244|PDB:3CH4}.
FT   HELIX       112    122       {ECO:0000244|PDB:3CH4}.
FT   HELIX       123    125       {ECO:0000244|PDB:3CH4}.
FT   STRAND      126    133       {ECO:0000244|PDB:3CH4}.
FT   HELIX       135    140       {ECO:0000244|PDB:3CH4}.
FT   TURN        147    151       {ECO:0000244|PDB:3CH4}.
FT   HELIX       153    156       {ECO:0000244|PDB:3CH4}.
FT   TURN        157    160       {ECO:0000244|PDB:3CH4}.
FT   STRAND      165    170       {ECO:0000244|PDB:3CH4}.
FT   HELIX       174    189       {ECO:0000244|PDB:3CH4}.
SQ   SEQUENCE   192 AA;  21995 MW;  D7E720D0DDCCA249 CRC64;
     MAPLGGAPRL VLLFSGKRKS GKDFVTEALQ SRLGADVCAV LRLSGPLKEQ YAQEHGLNFQ
     RLLDTSTYKE AFRKDMIRWG EEKRQADPGF FCRKIVEGIS QPIWLVSDTR RVSDIQWFRE
     AYGAVTQTVR VVALEQSRQQ RGWVFTPGVD DAESECGLDN FGDFDWVIEN HGVEQRLEEQ
     LENLIEFIRS RL
//
